EdgeMarket › What Avoro Capital Advisors Llc reported owning
What Avoro Capital Advisors Llc reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
10.2BPositions
32Quarter
2026-03-31Shown below
30largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| UTHR UNITED THERAPEUTICS Corp | 1.6B | 15.3% | 2.6M | 513.12 | +67.4% |
| ASND Ascendis Pharma A/S | 1.2B | 11.4% | 5.1M | 253.29 | +31.4% |
| MDGL MADRIGAL PHARMACEUTICALS, INC. | 951.8M | 9.4% | 1.8M | 516.74 | +31.9% |
| KRYS Krystal Biotech, Inc. | 746.3M | 7.3% | 2.9M | 346.58 | +137.6% |
| ARGX ARGENX SE | 730.2M | 7.2% | 1.0M | 1,039.78 | +57.3% |
| ARWR ARROWHEAD PHARMACEUTICALS, INC. | 670.9M | 6.6% | 10.7M | 87.11 | +331.2% |
| KYMR Kymera Therapeutics, Inc. | 622.6M | 6.1% | 7.5M | 119.80 | +182.9% |
| unmapped CUSIP 03753U106 | 491.7M | 4.8% | 12.2M | — | — |
| unmapped CUSIP 152309100 | 454.0M | 4.5% | 11.4M | — | — |
| CELC Celcuity Inc. | 385.2M | 3.8% | 3.4M | 93.53 | +91.8% |
| XENE Xenon Pharmaceuticals Inc. | 336.0M | 3.3% | 5.8M | 60.77 | +61.5% |
| GPCR Structure Therapeutics Inc. | 316.0M | 3.1% | 6.6M | 49.09 | +164.4% |
| unmapped CUSIP 880881107 | 300.2M | 3.0% | 5.7M | — | — |
| VERA Vera Therapeutics, Inc. | 236.9M | 2.3% | 5.9M | 32.27 | +46.0% |
| RVMD Revolution Medicines, Inc. | 228.0M | 2.2% | 2.3M | 209.46 | +479.3% |
| CYTK CYTOKINETICS INC | 219.7M | 2.2% | 3.3M | 76.84 | +105.9% |
| OCUL OCULAR THERAPEUTIX, INC | 104.3M | 1.0% | 12.3M | 11.08 | -7.4% |
| DMRA Damora Therapeutics, Inc. | 98.0M | 1.0% | 3.8M | 30.82 | +811.9% |
| QURE uniQure N.V. | 97.4M | 1.0% | 6.0M | 48.37 | +212.5% |
| TSHA Taysha Gene Therapies, Inc. | 97.0M | 1.0% | 21.7M | 6.09 | +112.2% |
| DFTX Definium Therapeutics, Inc. | 94.5M | 0.9% | 5.0M | 44.91 | +375.2% |
| unmapped CUSIP 834203309 | 77.0M | 0.8% | 2.3M | — | — |
| ALKS Alkermes plc. | 42.4M | 0.4% | 1.2M | 48.33 | +66.8% |
| SEPN Septerna, Inc. | 32.1M | 0.3% | 1.3M | 40.00 | +260.7% |
| VRDN Viridian Therapeutics, Inc.\DE | 29.3M | 0.3% | 1.5M | 24.29 | +33.9% |
| GHRS GH Research PLC | 25.3M | 0.2% | 1.8M | 28.33 | +121.7% |
| AVTX Avalo Therapeutics, Inc. | 21.1M | 0.2% | 1.4M | 19.83 | +115.1% |
| LXEO Lexeo Therapeutics, Inc. | 10.8M | 0.1% | 1.9M | 4.88 | +1.7% |
| WHWK Whitehawk Therapeutics, Inc. | 9.8M | 0.1% | 2.8M | 4.73 | +186.7% |
| MNKD MANNKIND CORP | 5.4M | 0.1% | 2.2M | 4.15 | +4.5% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →